RareCan
RareCan is a direct-to-patient clinical trial platform, harnessing the power of patients and data aiming to reduce costs and increase the success rate of rare cancer trials for the $143bn global cancer drug market. Raising to grow the team and develop platform capabilities.
Past Raises
| 2022 | £320,000 | Closed |
We act as an investment opportunity aggregator, collecting hundreds of investment opportunities from across the UK.
If you'd like your events, opportunities and news listed here please join free as an organisation.